Arjun Malhotra(@BadCapitalVC):yes @WisprFlow is a vitamin, not a painkiller. but it's defensible for plenty of reasons: it's a product with a very high-frequency use case, even up to 40x a day. there's no learning curve to adopting it, and it integrates seamlessly with your current workflows. and distribution has been incredible, driven heavily by word of mouth. subconscious adoption is a very underrated moat.

Arjun Malhotra

@BadCapitalVC

Investing in companies that don't make money @GoodCapitalVC

参加 February 2012

1.4K フォロー中 11.3K ファン

Arjun Malhotra@BadCapitalVC

2026.08.19 06:42

yes @WisprFlow is a vitamin, not a painkiller. but it's defensible for plenty of reasons: it's a product with a very high-frequency use case, even up to 40x a day. there's no learning curve to adopting it, and it integrates seamlessly with your current workflows. and distribution has been incredible, driven heavily by word of mouth. subconscious adoption is a very underrated moat.

Andrew Wilkinson@awilkinson

2026.08.18 19:40

I don’t know how Wispr Flow is a business in 2027. Literally weeks away from not needing to exist. I have never seen a clearer example of Feature Not a Product.